MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
TSX:MBX - Toronto Stock Exchange - CA59501P1045 - Common Stock - Currency: CAD
Overall MBX gets a fundamental rating of 7 out of 10. We evaluated MBX against 25 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making MBX a very profitable company, without any liquidiy or solvency issues. MBX is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make MBX suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
MBX had positive earnings in the past year.
MBX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
MBX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of MBX (4.89%) is better than 85.00% of its industry peers.
MBX's Return On Equity of 6.65% is amongst the best of the industry. MBX outperforms 90.00% of its industry peers.
The Return On Invested Capital of MBX (5.01%) is better than 90.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 6.65% | ||
| ROIC | 5.01% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MBX (8.34%) is better than 90.00% of its industry peers.
MBX's Profit Margin has improved in the last couple of years.
MBX has a Operating Margin of 10.70%. This is amongst the best in the industry. MBX outperforms 95.00% of its industry peers.
MBX's Operating Margin has improved in the last couple of years.
The Gross Margin of MBX (56.11%) is better than 80.00% of its industry peers.
MBX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.7% | ||
| PM (TTM) | 8.34% | ||
| GM | 56.11% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
MBX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, MBX has less shares outstanding
Compared to 5 years ago, MBX has more shares outstanding
MBX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.06 indicates that MBX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.06, MBX belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
The Debt to FCF ratio of MBX is 3.73, which is a good value as it means it would take MBX, 3.73 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.73, MBX belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
MBX has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
MBX's Debt to Equity ratio of 0.22 is fine compared to the rest of the industry. MBX outperforms 65.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 3.73 | ||
| Altman-Z | 4.06 |
ROIC/WACC0.62
WACC8.09%
2.3 Liquidity
MBX has a Current Ratio of 6.62. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 6.62, MBX belongs to the best of the industry, outperforming 85.00% of the companies in the same industry.
A Quick Ratio of 4.80 indicates that MBX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.80, MBX belongs to the top of the industry, outperforming 85.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 4.8 |
3. Growth
3.1 Past
The earnings per share for MBX have decreased strongly by -21.34% in the last year.
Measured over the past years, MBX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.58% on average per year.
MBX shows a small growth in Revenue. In the last year, the Revenue has grown by 2.73%.
The Revenue has been growing by 13.62% on average over the past years. This is quite good.
EPS 1Y (TTM)-21.34%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-64.59%
Revenue 1Y (TTM)2.73%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-28.12%
3.2 Future
The Earnings Per Share is expected to grow by 51.83% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 21.86% on average over the next years. This is a very strong growth
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MBX is valuated quite expensively with a Price/Earnings ratio of 48.50.
Based on the Price/Earnings ratio, MBX is valued cheaply inside the industry as 85.00% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 29.63. MBX is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 12.00, which indicates a correct valuation of MBX.
100.00% of the companies in the same industry are more expensive than MBX, based on the Price/Forward Earnings ratio.
MBX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.5 | ||
| Fwd PE | 12 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 95.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 90.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.74 | ||
| EV/EBITDA | 14.2 |
4.3 Compensation for Growth
MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 51.83% in the coming years.
PEG (NY)0.97
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (2/21/2025, 7:00:00 PM)
0.485
+0.01 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners15.2%
Ins Owner ChangeN/A
Market Cap65.22M
Analysts80
Price Target0.92 (89.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)12.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)50%
EPS NY rev (3m)50%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)9.31%
Revenue NY rev (3m)-7.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.5 | ||
| Fwd PE | 12 | ||
| P/S | 2.83 | ||
| P/FCF | 37.74 | ||
| P/OCF | 17.16 | ||
| P/B | 2.26 | ||
| P/tB | 2.63 | ||
| EV/EBITDA | 14.2 |
EPS(TTM)0.01
EY2.06%
EPS(NY)0.04
Fwd EY8.33%
FCF(TTM)0.01
FCFY2.65%
OCF(TTM)0.03
OCFY5.83%
SpS0.17
BVpS0.21
TBVpS0.18
PEG (NY)0.97
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 6.65% | ||
| ROCE | 6.95% | ||
| ROIC | 5.01% | ||
| ROICexc | 7.93% | ||
| ROICexgc | 9.7% | ||
| OM | 10.7% | ||
| PM (TTM) | 8.34% | ||
| GM | 56.11% | ||
| FCFM | 7.5% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-16.73%
ROICexcg growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 3.73 | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 124.49% | ||
| Cap/Sales | 9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.07% | ||
| Profit Quality | 89.93% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 4.8 | ||
| Altman-Z | 4.06 |
F-Score6
WACC8.09%
ROIC/WACC0.62
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.34%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-64.59%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)2.73%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-28.12%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y139.2%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-26.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.79%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y25.05%
OCF growth 3Y27.25%
OCF growth 5Y155.41%